Insulin aspart (AT278) vs insulin NPH

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

Insulin aspart (AT278)

Developed by Arecor Limited

Phase 1 in Type 2 Diabetespeptide
Partial signal

NCT05754424 · Phase 1 · completed

Every participant received AT278 and the active comparator insulin in random order, with neither participants nor staff knowing which was given at each visit, which is a solid design. But the trial measured a pharmacology lab readout rather than a real-world blood sugar or complication outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Area under the glucose infusion rate-time curve of insulin aspart (0 to 60 minutes): Glucose clamp trial in overweight/obese people with Type 2 Diabetes (NCT05754424, AT278 U500 vs NovoRapid U100 vs Humulin R U500, 41 participants per EASD 2024 data matching registry enrollment): primary non-inferiority endpoint met with statistical superiority -- 1.7-fold higher glucose-lowering effect in first 60 min (95% CI 1.32-2.96, p<0.0001). (met)

Result source: NCT05754424

insulin NPH · Humulin N

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin aspart (AT278)insulin NPH
HbA1c, change—Not reported—Not posted · NCT00604396
Body weight, change (kg)—Not reported12.6 vs 13vs Levemirn 42NCT01837680
HbA1c below 7%—Not reported—Not posted · NCT00604396
Fasting plasma glucose, change—Not reported—Not posted · NCT00604396
3-point MACE (% with event)—Not reported—Not posted · NCT00604396

HbA1c, change

Insulin aspart (AT278)
—Not reported
insulin NPH
—Not posted · NCT00604396

Body weight, change (kg)

Insulin aspart (AT278)
—Not reported
insulin NPH
12.6 vs 13vs Levemirn 42NCT01837680

HbA1c below 7%

Insulin aspart (AT278)
—Not reported
insulin NPH
—Not posted · NCT00604396

Fasting plasma glucose, change

Insulin aspart (AT278)
—Not reported
insulin NPH
—Not posted · NCT00604396

3-point MACE (% with event)

Insulin aspart (AT278)
—Not reported
insulin NPH
—Not posted · NCT00604396
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Insulin aspart (AT278)
Glucose clamp trial in overweight/obese people with Type 2 Diabetes (NCT05754424, AT278 U500 vs NovoRapid U100 vs Humulin R U500, 41 participants per EASD 2024 data matching registry enrollment): primary non-inferiority endpoint met with statistical superiority -- 1.7-fold higher glucose-lowering effect in first 60 min (95% CI 1.32-2.96, p<0.0001). NCT05754424 · Phase 1 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Insulin aspart (AT278): 0 of 4 rows · insulin NPH: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin NPH
Dropout rate
19.2%a
NCT01837680 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01837680 · Phase na · registry result, not featured evidence
Serious AEs
0%a
NCT01837680 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
biochemical event of hypoglycemia 26.9%
symptomatic hypoglycemia 21.2%
rash 11.5%
NCT01837680 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin NPH

Glucose mg/dL 6.08 vs 5.96 Levemir mmol/L
absolute value · mmol/L
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 109.5 mg/dL as posted
Glucose Target Attainment 66.7% (n=42) vs 77.8% (n=45) Levemir
event count · % of participants
NCT01837680 · Phase na · registry result, not featured evidence · converted to % from 28 Participants as posted
Time to Glycemic Control 1.15 vs 1.15 Levemir months
time to event · months
NCT01837680 · Phase na · registry result, not featured evidence · converted to months from 5 weeks as posted
Fasting Plasma Glucose mg/dL 5.59 vs 5.4 Levemir mmol/L
absolute value · mmol/L
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 100.7 mg/dL as posted
Postprandial Plasma Glucose mg/dL 6.39 vs 6.27 Levemir mmol/L
absolute value · mmol/L
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 115.2 mg/dL as posted
Weight 12.6 vs 13 Levemir kg
absolute change · kg
NCT01837680 · Phase na · registry result, not featured evidence · converted to kg from 27.7 lbs as posted
Birth Weight Grams 3230 vs 3235 Levemir g
absolute value · g
NCT01837680 · Phase na · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (AT278)'s landscape · insulin NPH's landscape